VEXIM Announces Successful Completion of Third Expert Symposium on VCF Management in Lisbon, Portugal

Regulatory News:

VEXIM (Paris:ALVXM) (FR0011072602 – ALVXM / PEA-PME eligible), a medical device company specializing in the minimally-invasive treatment of vertebral fractures, announces the successful completion of the 3^rd Expert Symposium on changing practice in the management of vertebral compression fractures (VCF) which took place from May 16 to 17, 2014 in Lisbon, Portugal.

This expert symposium "VCF Management: Changing Practice” was organized by Vexim and attended by more than 120 professionals representing different spine disciplines (orthopedic surgeons, trauma surgeons, neurosurgeons as well as interventional radiologists) from all over the world. The objective of this event, which was recognized internationally, was to promote interdisciplinary exchanges on best practices, experience and the latest VCF management trends.

The growing use of minimally-invasive techniques in particular has been supported by excellent clinical mid- and long-term results with the SpineJack^® implant, highlighted by two clinical studies presented by Prof. David Noriega (University hospital Valladolid, Spain) and Dr. Francaviglia (Palermo Hospital, Italy).

"This symposium was marked by fruitful and high level discussions on the latest developments in managing VCF,” stated Dr. Antonio Krüger, Orthopedic Trauma Surgeon at the Department of Trauma, Hand and Reconstructive Surgery of Philipp’s University Marburg (Germany). "We noted a clear trend in favor of percutaneous and minimally invasive surgery based on intravertebral implants to achieve vertebral height restoration in the event of vertebral compression fractures."

Vincent Gardès, CEO of VEXIM, concluded: "I would like to thank the entire team that organized the Expert Symposium as well as all the participants who contributed to the success of this third event. The growing interest by spine professional community in this annual conference served as further encouragement to pursue our efforts to promote innovative solutions for the treatment of vertebral compression fractures and for which SpineJack^® now represents an international benchmark."

***

About VEXIM, the innovative back microsurgery specialist
Based in Balma, near Toulouse (France), VEXIM is a medical device company created in February 2006. The Company has specialized in the creation and marketing of mini-invasive solutions for treating traumatic spinal pathologies. Benefitting from the financial support of its longstanding shareholders, Truffle Capital¹ and Banexi Venture, and from OSEO public subsidies, VEXIM has designed and developed the SpineJack®, a unique implant capable of repairing a fractured vertebra and restoring the balance of the spinal column. The Company currently has 57 staff. It has its own sales teams in France, Germany, Italy, Spain, Switzerland and the United Kingdom, as well as distributors notably in Argentina, India, Taiwan, Belgium, South Africa, Colombia, Chile, Panama and in the following countries where the product is currently being registered: Mexico, Brazil, Venezuela, Ecuador and Peru. VEXIM has been listed on NYSE Alternext Paris since May 3, 2012.

For further information, please go to www.vexim.com

SpineJack®², a revolutionary implant for treating Vertebral Compression Fractures
The revolutionary aspect of the SpineJack® lies in its ability to restore a fractured vertebra to its original shape, restore the spinal column’s optimal anatomy and thus remove pain and enable the patient to recover their functional capabilities. Thanks to a specialized range of instruments, inserting the implants into the vertebra is carried out by mini-invasive surgery, guided by X-ray, in approximately 30 minutes, enabling the patient to be discharged shortly after surgery. The SpineJack® range consists of 3 titanium implants with 3 different diameters, thus covering 95% of vertebral compression fractures and all patient morphologies. SpineJack® technology benefits from the support of international scientific experts in the field of spine surgery and worldwide patent protection until 2029.

• Name: VEXIM
• ISIN code: FR0011072602
• Ticker: ALVXM

¹ Founded in 2001 in Paris, Truffle Capital is a leading independent European private equity firm. It is dedicated to investing in and building technology leaders in the IT, life sciences and energy sectors. Truffle Capital manages €550m via FCPRs and FCPIs, the latter offering tax rebates (funds are blocked during 7 to 10 years). For further information, please visit www.truffle.fr and www.fcpi.fr.
² This medical device is a regulated health product that, with regard to these regulations, bears the CE mark. Please refer to the Instructions for Use.